BR112018002138A2 - composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões - Google Patents

composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões

Info

Publication number
BR112018002138A2
BR112018002138A2 BR112018002138-5A BR112018002138A BR112018002138A2 BR 112018002138 A2 BR112018002138 A2 BR 112018002138A2 BR 112018002138 A BR112018002138 A BR 112018002138A BR 112018002138 A2 BR112018002138 A2 BR 112018002138A2
Authority
BR
Brazil
Prior art keywords
pyrrolidin
prophylaxis
oxo
phenyl
methyl
Prior art date
Application number
BR112018002138-5A
Other languages
English (en)
Inventor
Zvejniece Liga
Dambrova Maija
SVALBE Baiba
Vavers Edijs
Kalvins Ivars
Veinbergs Grigorijs
Stonans Ilmars
Misane Ilga
Vorona Maksims
Cernobrovijs Aleksandrs
Original Assignee
Latvian Institute Of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute Of Organic Synthesis filed Critical Latvian Institute Of Organic Synthesis
Publication of BR112018002138A2 publication Critical patent/BR112018002138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

uso de 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida (i) o uma sal farmaceuticamente aceitável no fabrico de um medicamento para profilaxia e tratamento de convulsões.
BR112018002138-5A 2015-08-03 2016-08-02 composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões BR112018002138A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179448.4A EP3127539A1 (en) 2015-08-03 2015-08-03 Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
EP15179448.4 2015-08-03
PCT/IB2016/054641 WO2017021881A1 (en) 2015-08-03 2016-08-02 Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures

Publications (1)

Publication Number Publication Date
BR112018002138A2 true BR112018002138A2 (pt) 2018-09-11

Family

ID=53776429

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002138-5A BR112018002138A2 (pt) 2015-08-03 2016-08-02 composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões

Country Status (11)

Country Link
US (1) US10105348B2 (pt)
EP (2) EP3127539A1 (pt)
JP (1) JP6470870B2 (pt)
CN (1) CN107921019B (pt)
BR (1) BR112018002138A2 (pt)
CA (1) CA2988045A1 (pt)
EA (1) EA036085B1 (pt)
MX (1) MX2018001355A (pt)
TW (1) TWI643617B (pt)
UA (1) UA120886C2 (pt)
WO (1) WO2017021881A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
CA2741041C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
LV14346B (lv) 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Also Published As

Publication number Publication date
CN107921019A (zh) 2018-04-17
EP3331523B1 (en) 2021-10-13
EP3331523A1 (en) 2018-06-13
EA036085B1 (ru) 2020-09-24
TW201709908A (zh) 2017-03-16
EP3127539A1 (en) 2017-02-08
CN107921019B (zh) 2021-03-05
WO2017021881A1 (en) 2017-02-09
MX2018001355A (es) 2018-05-22
US20180200227A1 (en) 2018-07-19
TWI643617B (zh) 2018-12-11
UA120886C2 (uk) 2020-02-25
JP6470870B2 (ja) 2019-02-13
JP2018522019A (ja) 2018-08-09
EA201890122A1 (ru) 2018-05-31
CA2988045A1 (en) 2017-02-09
US10105348B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CL2015003442A1 (es) Derivados heterociclicos
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016029369A2 (pt) oligômero antissentido, composição farmacêutica e método para tratamento de distrofia muscular, uso de um oligômero antissentido ou um sal ou hidrato farmaceuticamente aceitável do mesmo, e, métodos para fabricação e para triagem de um oligômero antissentido
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112017016396A2 (pt) composto, composição farmacêutica, uso de um composto, e, método.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
BR112018002138A2 (pt) composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.